Medication info
Hyusiga Duo Sustained Release Tablet 10/1000 mg (Dapagliflozin, Metformin)

Hyusiga Duo Sustained Release Tablet 10/1000 mg (Dapagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Yellow, oval-shaped, bilayered, biconvex, sustained-release film-coated tablet
Packaging
Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300360 · Approved 2023.01.27 · Insurance code 670402400,670609310

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment with this medicine may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause changes in glycemic control, changes in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes when administered alongside dietary and exercise regimens. It is particularly applicable to type 2 diabetes patients who are not sufficiently controlled and have cardiovascular diseases or risk factors. However, the impact related to the occurrence of cardiovascular events should be referred to in professional information. Overall, this medication is utilized as a therapeutic agent that assists in diabetes management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment with this medicine may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause changes in glycemic control, changes in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Precautions

This medication consists of two components and is primarily used for blood sugar control in type 2 diabetes patients. Before taking this medication, it is essential to verify that renal function is normal, and it should not be prescribed to patients with severe renal impairment. This medication should not be used in cases of acute illness affecting renal function, such as severe infections, dehydration, cardiovascular issues, acute myocardial infarction, or sepsis. Women who are pregnant or breastfeeding should not take this medication, and it is contraindicated in patients with certain genetic disorders such as lactase deficiency. This medication can rarely cause serious metabolic complications such as lactic acidosis, so patients and caregivers must immediately inform healthcare professionals if symptoms such as malaise, muscle pain, difficulty breathing, or abdominal pain occur. When used in combination with insulin or sulfonylurea medications, there may be an increased risk of hypoglycemia, necessitating close monitoring of blood sugar changes and dosage adjustments as needed. This medication may cause reduced fluid volume and hypotension, so elderly patients or those on diuretics should regularly check blood pressure and fluid status. There is an increased risk of genital and urinary tract infections, and if any infection symptoms appear, treatment should be sought immediately, with further caution advised for patients with a history of recurrent infections. It is advisable not to use this medication in patients with hepatic dysfunction, and if symptoms of hepatic functional abnormalities occur, immediate consultation with a healthcare provider is necessary. Excessive alcohol consumption should be avoided while taking this medication, and if any abnormal symptoms such as sudden weight loss, fever, or pain or swelling around the genital area occur, immediate medical care should be sought. Before undergoing surgery or radiological iodine contrast examinations, this medication should be discontinued for a specified period, and administration should resume only after confirming normal kidney function. Elderly patients often experience renal function decline, so dose adjustments and regular renal function tests are necessary, and the risk of vitamin B12 deficiency should also be periodically checked. The safety and efficacy of this medication have not been established in children, so it should not be administered to pediatric patients. In the event of overdose, immediate medical action is required, and in the case of the metformin component, drug removal through dialysis is possible, following the healthcare provider's instructions. This medication does not significantly affect the ability to drive or operate machinery, but caution is needed if symptoms such as dizziness occur. Finally, this medication should be kept out of the reach of children and stored in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • pruritus of the genitals
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • tendinitis
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinosis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • benign prostatic hyperplasia
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a sealed container to prevent air exposure, and the storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature. This storage method helps in maintaining the medication's efficacy and preventing degradation.

Appearance and packaging

Appearance

Yellow, oval-shaped, bilayered, biconvex, sustained-release film-coated tablet

Package unit

Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.